Koers Mateon Therapeutics Inc Nasdaq
Aandelen
US57667K1097
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | 0,07 0,06 | Marktkapitalisatie | 15,27 mln. 14,08 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | 5 mln. 4,61 mln. | Nettowinst (verlies) 2023 | -7 mln. -6,45 mln. | EV/omzet 2022 | - |
Nettoschuld 2022 | 11,02 mln. 10,16 mln. | Nettoschuld 2023 | 12,4 mln. 11,44 mln. | EV/omzet 2023 | 395.316.686 x |
K/w-verhouding 2022 |
4,5
x | K/w-verhouding 2023 |
-1,91
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 45,17% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22-04-19 |
Director of Finance/CFO | 57 | 01-07-19 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 06-01-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Steven King
BRD | Director/Board Member | 59 | 11-05-20 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 11-05-20 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+12,30% | 118 mld. | |
+12,15% | 106 mld. | |
-8,14% | 23,4 mld. | |
-1,69% | 21,78 mld. | |
-10,60% | 18,09 mld. | |
-41,25% | 16,72 mld. | |
-15,33% | 15,97 mld. | |
+5,80% | 14,03 mld. | |
+28,03% | 11,67 mld. |